BioCentury | Jun 17, 2020
Emerging Company Profile

Lightspeed, Klausner back Stanford cell therapy spinout Orca in new $192M round

With the completion of a new $192 million series D round, Stanford spinout Orca Bio has now raised nearly $300 million to develop and manufacture allogeneic cell therapies that use controlled formulations designed to reduce...
BioCentury | Jun 12, 2020
Finance

Investor call for ethical activity during COVID-19 fight

A group of mostly Dutch investors is calling on the biopharma sector to proactively collaborate and act responsibly in the fight against COVID-19. Companies that don’t comply risk divestment. While the group is actively monitoring...
BioCentury | May 21, 2020
Product Development

Industry is a white knight right now. Don’t throw it away

Biopharma is having a moment. All eyes are on drug, diagnostic and vaccine developers to get us out of this crisis and back to work. Now, companies -- individually and collectively -- must make good...
BioCentury | May 16, 2020
Politics, Policy & Law

New BIO leader McMurry-Heath to focus on patients and innovation

BIO is looking to its new CEO and President, Michelle McMurry-Heath, to serve as a new face and voice for the industry, and to refocus the organization on patients and on creating the innovations they...
BioCentury | May 15, 2020
Finance

As biotech IPO pace quickens, ADC Therapeutics garners largest postmoney valuation of the year

Adding to a steady drip of biotechs testing U.S. public markets, ADC Therapeutics became the latest to climb on its trading debut after pricing an upsized IPO. ADC Therapeutics S.A. (NYSE:ADCT) rose $10.65 (56%) to...
BioCentury | May 12, 2020
Politics, Policy & Law

FDA’s hydroxychloroquine test

COVID-19 is testing FDA’s leadership. The agency’s performance will affect both the health of COVID-19 patients as well as public trust in the agency. One of many challenges facing FDA is whether to keep in...
BioCentury | May 5, 2020
Product Development

As FDA tightens reins on COVID-19 antibody testing, Roche unveils test specs via EUA

FDA’s reversal of its hands-off policy on antibody tests for the novel coronavirus, coupled with its authorization of a highly anticipated test from Roche, is raising the bar for COVID-19 serology. Yet accessing enough patient...
BioCentury | May 2, 2020
Product Development

Good test hunting: FDA authorizations point to benchmarks for COVID-19 serology

The critical role of COVID-19 antibody testing in reopening society -- combined with controversy around the regulatory flexibility these tests have received and reports that some are performing poorly -- have put all eyes on...
BioCentury | Apr 29, 2020
Product Development

Highlights from AACR’s first annual virtual meeting show mixed results for I/O combos, promise for new targets, modalities

Immuno-oncology combinations showed mixed results at the first of two virtual annual meetings this year of the American Association for Cancer Research, with PD-L1 inhibitor Tecentriq atezolizumab reporting two negative readouts and uninspiring monotherapy data...
BioCentury | Apr 29, 2020
Politics, Policy & Law

Readout for Gilead’s remdesivir in COVID-19 could warrant emergency use authorization

Remdesivir is the new standard of care for COVID-19, NIAID director Anthony Fauci said Wednesday. Other treatments will be compared with Gilead’s antiviral, and the therapy will be combined with other investigational drugs including anti-inflammatory...
Items per page:
1 - 10 of 1027